Abstract
Objectives: To elucidate genetic polymorphisms of the matrix metalloproteinases ( MMPs ) MMP 1 (rs1799750) , MMP 2 (rs243865) , MMP 9 (rs3918242) , MMP 12 (rs2276109) and tissue inhibitors of MMPs ( TIMPs ) TIMP 1 (rs2070584) and TIMP 3 (rs9619311) genes that may be involved in susceptibility to bladder cancer ( BC ). Patients and Methods: We enrolled 241 patients with BC and 199 controls. Genomic DNA samples were extracted from peripheral blood and polymorphisms were analysed by high‐resolution melting analysis and by real‐time polymerase chain reaction using T aq M an fluorescent probes. Results: Of the six evaluated polymorphisms of MMPs and TIMPs , only one was found to be associated with BC risk. There was a significant difference for MMP 1 (rs1799750) 2 G /1 G +1 G /1 G genotype (odds ratio [ OR ] 0.62, 95% confidence interval [ CI ] 0.39–0.98; P = 0.042). Additionally, there was a joint effect of this genotype on BC risk among ‘ever smokers’ ( OR 0.51, 95% CI 0.28–0.89; P = 0.019), but not in ‘never smokers’. The combined genotype MMP 2 –1306 C / T (rs243865) allele T with MMP 9 –1562 C / T (rs3918242) allele T was found to increase BC risk ( OR 2.00, 95% CI 1.10–3.62; P = 0.022). Conclusions: Our results suggest that genetic variations in five polymorphisms of MMPs and TIMPs are not associated with a high risk of BC . Only MMP 1 polymorphism may be related to the risk of BC , notably in ‘ever smokers’. Our study suggests that the effects of polymorphisms of MMPs and TIMPs on BC risk deserve further investigation.

This publication has 49 references indexed in Scilit: